Overview
Tirzepatide is a dual GIP/GLP-1 agonist — once-weekly injection with more weight loss than semaglutide (~22% at max dose). Mounjaro for diabetes; Zepbound for weight loss and OSA with obesity.
Treatment
Weekly injection, escalated slowly. Superior weight loss and A1c reduction vs semaglutide in head-to-head trials.